bc cancer bevacizumab

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
bc cancer bevacizumab	0.58	0.2	9339	29	21
bc	0.72	0.5	4642	97	2
cancer	1.38	0.9	2834	35	6
bevacizumab	1.28	0.2	2593	66	11

Keyword	CPC	PCC	Volume	Score
bc cancer bevacizumab	1.18	0.2	2229	49
bevacizumab irinotecan glioblastoma bc cancer	1.66	0.9	8699	94
bc cancer agency bevacizumab	0.76	0.1	1313	90
irinotecan bevacizumab glioblastoma protocol	0.99	0.4	5049	29
bc cancer atezolizumab bevacizumab	0.19	1	3655	10
bevacizumab glioblastoma fda approval	1.98	0.8	7930	27
bevacizumab in lung cancer	1.18	0.7	6999	36
bevacizumab in colorectal cancer	0.67	0.7	353	26
bevacizumab and pembrolizumab glioblastoma	0.74	0.8	1478	81
capecitabine irinotecan and bevacizumab	1.28	0.4	4638	49
bevacizumab for colon cancer	0.64	0.3	8672	12
bevacizumab erlotinib renal cell carcinoma	1.91	0.4	5017	62
bevacizumab metastatic colorectal cancer	0.85	0.6	391	98
bevacizumab right side colon cancer	0.03	0.4	3853	80
irinotecan single agent bc cancer	1.94	0.1	6584	95
bevacizumab capecitabine colorectal cancer	1.84	1	934	68
bevacizumab for the treatment of angiosarcoma	1.23	0.9	9603	82
lomustine and bevacizumab glioblastoma	0.94	0.3	7204	49
bevacizumab in ovarian cancer	1.28	0.7	1101	70
bevacizumab chemotherapy or immunotherapy	1.72	0.7	7431	79
nivolumab ipilimumab colorectal cancer	0.42	0.5	8066	99
bevacizumab-bvzr	1.26	1	1774	52
nivolumab ipilimumab lung cancer	0.93	0.3	7809	84
nivolumab for the treatment of cancer	1.34	0.4	480	89
nivolumab ipilimumab hepatocellular carcinoma	0.94	0.2	6998	41